Insulin Therapy and Type 2 Diabetes: Management of Weight Gain
被引:32
|
作者:
McFarlane, Samy I.
论文数: 0引用数: 0
h-index: 0
机构:
SUNY, Div Endocrinol, Coll Med, Downstate & Kings Cty Med Ctr, Brooklyn, NY 11203 USASUNY, Div Endocrinol, Coll Med, Downstate & Kings Cty Med Ctr, Brooklyn, NY 11203 USA
McFarlane, Samy I.
[1
]
机构:
[1] SUNY, Div Endocrinol, Coll Med, Downstate & Kings Cty Med Ctr, Brooklyn, NY 11203 USA
The potential for insulin-related weight gain in patients with type 2 diabetes presents a therapeutic dilemma and frequently leads to delays in the initiation of insulin therapy. It also poses considerable challenges when treatment is intensified. Addressing insulin-related weight gain is highly relevant to the prevention of metabolic and cardiovascular consequences in this high-risk population with type 2 diabetes. In addition to lifestyle changes (eg, diet and exercise) and available medical interventions to minimize the risk of weight gain with insulin treatment, familiarity with the weight gain patterns of different insulins may help deal with this problem. The use of basal insulin analogs may offer advantages over conventional human insulin preparations in terms of more physiologic time-action profiles, reduced risk of hypoglycemia, and reduced weight gain.
机构:
Vet Affairs San Diego Healthcare Syst, Sect Diabet Metab, La Jolla, CA 92161 USAVet Affairs San Diego Healthcare Syst, Sect Diabet Metab, La Jolla, CA 92161 USA
Davis, T
Edelman, SV
论文数: 0引用数: 0
h-index: 0
机构:
Vet Affairs San Diego Healthcare Syst, Sect Diabet Metab, La Jolla, CA 92161 USAVet Affairs San Diego Healthcare Syst, Sect Diabet Metab, La Jolla, CA 92161 USA
机构:
Univ Michigan, Med Ctr, Div Metab Endocrinol & Diabet, Dept Internal Med, 1000 Wall St 48105, Ann Arbor, MI 48109 USAUniv Michigan, Med Ctr, Div Metab Endocrinol & Diabet, Dept Internal Med, 1000 Wall St 48105, Ann Arbor, MI 48109 USA